维普中文期刊产品整合服务
26篇 您的检索式:作者名="Gallazzi"
    题名 作者 年代 出处 被引量
1Predicting lower limb periprosthetic joint infections: A review of risk factors and their classification显示文摘AIM To undertook a systematic review to determine factors that increase a patient's risk of developing lower limb periprosthetic joint infections(PJI).METHODS This systematic review included full-text studies that reviewed risk factors of developing either a hip or knee PJI following a primary arthroplasty published from January 1998 to November 2016. A variety of keywords were used to identify studies through international databases referencing hip arthroplasty, knee arthroplasty, infection, and risk factors. Studies were only included if they included greater than 20 patients in their study cohort, and there was clear documentation of the statistical parameter used; specifically P-value, hazard ratio, relative risk, or/and odds ratio(OR). Furthermore a quality assessment criteria for the individual studies was undertaken to evaluate the presence of record and reporting bias. RESULTS Twenty-seven original studies reviewing risk factors relating to primary total hip and knee arthroplasty infections were included. Four studies(14.8%) reviewed PJI of the hip, 3(11.21%) of the knee, and 20(74.1%) reviewed both joints. Nineteen studies(70.4%) were retrospective and 8(29.6%) prospective. Record bias was identified in the majority of studies(66.7%). The definition of PJI varied amongst the studies but there was a general consensus to define infection by previously validated methods. The most significant risks were the use of preoperative high dose steroids(OR = 21.0, 95%CI: 3.5-127.2, P < 0.001), a BMI above 50(OR = 18.3, P < 0.001), tobacco use(OR = 12.76, 95%CI: 2.47-66.16, P= 0.017), body mass index below 20(OR = 6.00, 95%CI: 1.2-30.9, P = 0.033), diabetes(OR = 5.47, 95%CI: 1.77-16.97, P = 0.003), and coronary artery disease(OR = 5.10, 95%CI: 1.3-19.8, P = 0.017).CONCLUSION We have highlighted the need for the provider to optimise modifiable risk factors, and develop strategies to limit the impact of non-modifiable factors.David A George Lorenzo Drago Sara Scarponi Enrico Gallazzi Fares S Haddad Carlo L Romano 2017World Journal of Orthopedics2017,8,5:3
2Effects of Lactoba-cillus acidophilus D2/CSL on laying hen performance显示文摘Gallazzi D Giardini A Mangiagalli M G 2008Ital J An- im Sci2008,7,1:1
3Treatment of benign nodular goiter with mildly suppressive doses of L-thyroxine : effects on bone mineral density and on nodule size 显示文摘Baldini M Gallazzi M Orsatti A 2002J Intern Med2002,251,5:1
4Molecular imaging of bcl-2 expression in small lymphocytic lymphoma using 111In-labeled PNA-peptide conjugates显示文摘Jia F Figueroa SD Gallazzi F 2008J Nucl Med2008,49,:1
5111In-labeled lactam bridge-cyclized α-melanocyte stimulating hormone peptide analogues for melanoma imaging显示文摘Miao Y B Gallazzi F Guo H X 2008Bioconjugate Chemistry2008,19,2:1
6Effect of DOTA position on melanoma targeting and pharmacokinetic properties of111In-labeled lactam bridge-cyclized α-melanocyte stimulating hormone peptide显示文摘Guo H X Yang J Q Gallazzi F 2009Bioconjugate Chemistry2009,20,11:1
7Effects of the amino acid linkers on melanoma-targeting and pharmacokinetic properties ofIndium-111-labeled lactam bridge-cyclized α-MSH peptides显示文摘Guo H Yang J Gallazzi F 2011Journal of Nuclear Medicine2011,52,4:1
8Gallium-67-labeled lactam bridge-cyclized alpha-MSH peptides with enhanced melanoma uptake and reduced renal uptake显示文摘Guo H X Gallazzi F Miao Y B 2012Bioconjugate Chemistry2012,23,6:1
9Radiometal-labeled peptide- PNA conjugates for targeting bcl-2 expression: preparation, characterization, and in vitro mRNA binding显示文摘Lewis MR Jia F Gallazzi F 2002Bioconjug Chem2002,13,6:1
10Gallium-67-labeled lactam bridge-cyclized alpha-MSH peptides with enhanced melanoma uptake and reduced renal uptake显示文摘Guo H Gallazzi F Miao Y 2012Bioconjugate chemistry2012,23,6:1
11Reduction of the ring size of radiolabeled lactam bridge-cyclized alpha-MSH peptide resulting in enhanced melanoma uptake显示文摘Guo H Yang J Gallazzi F 2010Journal of Nuclear Medicine2010,51,3:1
12Desflurane preconditioning in coronary artery bypass graft surgery:a double-blinded,randomised and placebo-controlled study显示文摘Meco M Cirri S Gallazzi C 2007Eur J Cardiothorac Surg2007,32,2:1
13Surgical treatment of synchronous multiple lung cancer located in a different lobe or lung: high survival in node-negative subgroup 显示文摘Luca Voltolini Cristian Rapicetta Luca Luzzi Claudia Ghiribelli Piero Paladini Felice Granato Mariasole Gallazzi Giuseppe Gotti 2010European Journal of Cardio-Thoracic Surgery2010,,5:1
14Desflurane preconditioning in coronary artery bypass graft surgery : a double - blinded, randomised and placebo- controlled study显示文摘MECO M CIRRI S GALLAZZI C 2007Eur J Cardiothorae Surg2007,32,2:1
15The role of diagnostic imaging in synovial sarcoma: our experience显示文摘Marzano L Failoni S Gallazzi M Garbagna P 2004Radiol Med (Torino)2004,107,:1
16Synthesis of rsdiometal-labeled and fluorescent cell-permeating peptide-PNA conjugates for targeting the bcl-2proto-oncogene显示文摘Gallazzi F Wang Y Jia F 2003Bioconjug Chem2003,6,:1
17The ages and metallieities of galaxies in the local uni-verse显示文摘GALLAZZI A CHARLOT S BRINCHMANN J ct al 2005Monthly Notices of the Royal Astronomical Soci-ety2005,362,:1
18Desflurane preconditioning in coronary artery bypass graft surgery:a double-blinded,randomised and placebo-controlled study显示文摘Massimo Meco Silvia Cirri Chiara Gallazzi Giulia Magnani 2007European Journal of Cardio-Thoracic Surgery2007,32,:1
19Calcific tendinitis of the rectus femoris:a rare cause of snapping hip显示文摘Pierannunzii L Tramontana F Gallazzi M 0,,:1
20Desflurane preconditioning in coronary artery bypass graft surgery: a double-blind, randomized and placebo-c- ontrolled study显示文摘Meco M Cirri S Gallazzi C 2007Eur J Cardiothorae Surg2007,32,:1
返回顶部 每页显示:
共2页 首页 上一页 第1页 下一页 末页 /2 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费